Lantheus Holdings
United States
64 articles about Lantheus Holdings
-
While the candidate was effective in Phase III results, Point’s stock price fell following the announcement.
-
Lantheus and POINT Biopharma Announce Positive Topline Results from Pivotal SPLASH Trial in Metastatic Castration-Resistant Prostate Cancer
12/18/2023
Lantheus Holdings, Inc. today announced statistically significant topline results from the pivotal phase 3 SPLASH study evaluating the efficacy and safety of 177 Lu-PNT2002, a prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (RLT).
-
Lantheus and POINT Biopharma Announce FDA Grants Fast Track Designation for 177Lu-PNT2002 for the Treatment of Metastatic Castration Resistant Prostate Cancer
4/24/2023
Lantheus Holdings, Inc. and POINT Biopharma Global, Inc. today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for 177Lu-PNT2002 for the treatment of metastatic castration resistant prostate cancer (mCRPC).
-
POINT Biopharma Reports Third Quarter 2022 Financial Results and Announces Strategic Collaboration and Exclusive License Agreements with Lantheus Holdings
11/14/2022
POINT Biopharma Global Inc. today announced financial results for the third quarter ended September 30, 2022, and provided an update on business highlights, including the announcement of a strategic collaboration and exclusive license agreements with Lantheus Holdings Inc.
-
Lantheus and POINT Biopharma Announce Strategic Collaboration and Exclusive License Agreements for the Commercialization of PNT2002 & PNT2003
11/14/2022
Lantheus Holdings, Inc. and POINT Biopharma Global Inc. today announced a set of strategic collaboration agreements in which Lantheus will license exclusive worldwide rights1 to POINT’s PNT2002 and PNT2003 product candidates.
-
GE Healthcare and Lantheus Phase III Clinical Trial Finds [18F]flurpiridaz PET Radiotracer Could Improve Detection of Coronary Artery Disease
9/13/2022
GE Healthcare and Lantheus Phase III Clinical Trial Finds [ 18 F]flurpiridaz PET Radiotracer Could Improve Detection of Coronary Artery Disease.
-
A recent report predicts multiple acquisitions are set to be announced in the second half of the year, particularly by companies that have strong revenue streams from COVID-19 products.
-
Radiopharm Enters Into Strategic Collaboration With Lantheus and Assumes PD-L1 Licensing Agreement From Nanomab
8/4/2022
Radiopharm Theranostics is pleased to announce that it has entered a collaboration agreement with Lantheus for the mutually beneficial development of NM-01, a nanobody made using genetically engineered camelid derived single domain antibodies, that can be labelled with radioisotopes to potentially diagnose and treat multiple tumor types.
-
Lantheus Holdings, Inc. Reports Second Quarter 2021 Financial Results
7/28/2021
Lantheus Holdings, Inc., an established leader and fully integrated provider of innovative imaging diagnostics, targeted therapeutics and artificial intelligence solutions to find, fight and follow serious medical conditions, reported financial results for its second quarter ended June 30, 2021.
-
Lantheus Holdings to Host Second Quarter 2021 Earnings Conference Call and Webcast on July 28, 2021 at 8:00 a.m. Eastern Time
7/14/2021
Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH) today announced that it will host a conference call and webcast at 8:00 a.m. ET on Wednesday, July 28, 2021, to discuss its financial and operating results for the second quarter of 2021.
-
Lantheus To Present Piflufolastat F 18 Data at the Virtual Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2021 Annual Meeting
6/14/2021
Lantheus Holdings, Inc. announced that data from the piflufolastat F 18 (formerly known as 18 F-DCFPyL) CONDOR pivotal trial will be presented at the Virtual Society of Nuclear Medicine and Molecular Imaging (SNMMI) annual meeting.
-
Lantheus Receives U.S. FDA Approval of PYLARIFY® (piflufolastat F 18) Injection, the First and Only Commercially Available PSMA PET Imaging Agent for Prostate Cancer
5/27/2021
Lantheus Receives U.S. FDA Approval of PYLARIFY ® (piflufolastat F 18) Injection, the First and Only Commercially Available PSMA PET Imaging Agent for Prostate Cancer PYLARIFY will be available immediately to imaging centers in parts of the mid-Atlantic and southern regions and is expected to be broadly available throughout the U.S. by year end
-
It’s a busy week for the U.S. Food and Drug Administration, with a number of drug approvals on the calendar and an advisory committee meeting. Read on for more information.
-
Lantheus Holdings Announces Presentation Featuring 18F-DCFPyL PET/CT, its PSMA-Targeted Prostate Cancer Imaging Agent at the 2021 ASCO Annual Meeting
5/21/2021
Lantheus Holdings Announces Presentation Featuring 18 F-DCFPyL PET/CT, its PSMA-Targeted Prostate Cancer Imaging Agent at the 2021 ASCO Annual Meeting
-
Lantheus Holdings to Present at the Jefferies Virtual Healthcare Conference - May 20, 2021
5/20/2021
Lantheus Holdings, Inc., an established leader and fully integrated provider of innovative imaging diagnostics, targeted therapeutics and artificial intelligence solutions to find, fight and follow serious medical conditions, announced Mary Anne Heino, President and Chief Executive Officer, and Bob Marshall, Chief Financial Officer and Treasurer, will present at the Jefferies Virtual Healthcare Conference at 10:30 a.m. ET on Thursday, June 3.
-
Lantheus Holdings, Inc. Reports First Quarter 2021 Financial Results
5/4/2021
Worldwide revenue of $92.5 million for the first quarter 2021, representing an increase of 2.0% from the prior year period Net income of $9.0 million for the first quarter 2021, compared to net income of $3.3 million in the prior year period
-
Lantheus Holdings to Host First Quarter 2021 Earnings Conference Call and Webcast on May 4, 2021 at 8:00 a.m. Eastern Time
4/20/2021
Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH) today announced that it will host a conference call and webcast at 8:00 a.m. ET on Tuesday, May 4, 2021, to discuss its financial and operating results for the first quarter of 2021.
-
Lantheus Expands R&D Leadership Team with Key New Hires
4/7/2021
Lantheus Holdings, Inc., an established leader and fully integrated provider of innovative imaging diagnostics, targeted therapeutics and artificial intelligence solutions to Find, Fight and Follow serious medical conditions, announced the hiring of Dr. Bela Denes and Dr. Iryna Teslenko.
-
Lantheus Announces Retirement of Michael P. Duffy, Senior Vice President and General Counsel
4/1/2021
Lantheus Holdings, Inc. (NASDAQ: LNTH) (Lantheus), an established leader and fully integrated provider of innovative imaging diagnostics, targeted therapeutics and artificial intelligence solutions to Find, Fight and Follow serious medical conditions, today announced that Michael P. Duffy, Senior Vice President, Law and Public Policy and General Counsel will retire from Lantheus on June 4, 2021
-
Lantheus Acquires Rights to Innovative Imaging Biomarker Targeting Fibroblast Activation Protein (FAP) from Noria
3/30/2021
Lantheus Holdings, Inc. (NASDAQ: LNTH) (Lantheus), an established leader and fully integrated provider of innovative imaging diagnostics, targeted therapeutics and artificial intelligence solutions to Find, Fight and Follow serious medical conditions, announced today it has acquired the exclusive, worldwide rights to develop, manufacture and commercialize NTI-1309, an innovative PET oncology imaging agent from No